![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 20-Jun-2012[ | E-mail |
Share ] Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
A potential new approach for treating urinary tract infections (UTIs) which affect millions of people annually without traditional antibiotics is being reported in ACS' Journal of Medicinal Chemistry. It involves so-called FimH antagonists, which are non-antibiotic compounds and would not contribute to the growing problem of antibiotic resistance bacteria.
Beat Ernst and colleagues explain that antibiotics are the mainstay treatment for UTIs. Bacteria, however, are developing resistance to common antibiotics, with the emergence of "superbugs" that shrug off some of the most powerful new antibiotics. Thus, the scientists decided to try a new approach developing substances that target bacteria virulence factors, inhibiting them from sticking to the inside of the urinary bladder. Hence, microbes are not able to launch an infection and, furthermore, this new class of antimicrobials is expected to exhibit less selection pressure and, therefore, a reduced potential for the emergence of resistance.
The scientists describe the development of anti-adhesion molecules that specifically interfere with the attachment of bacteria to human bladder cells. The most potent of the substances, an indolinylphenyl mannoside, prevented a UTI from developing in mice (stand-ins for humans in this kind of experiment) for more than eight hours. In the in vivo treatment study, a very low dose of 25 g per mouse reduced the amount of bacteria in the bladder of the animals by almost 10,000 times, which is comparable to the standard antibiotic treatment with ciprofloxacin.
###
The authors acknowledge funding from the Swiss National Science Foundation.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 20-Jun-2012[ | E-mail |
Share ] Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
A potential new approach for treating urinary tract infections (UTIs) which affect millions of people annually without traditional antibiotics is being reported in ACS' Journal of Medicinal Chemistry. It involves so-called FimH antagonists, which are non-antibiotic compounds and would not contribute to the growing problem of antibiotic resistance bacteria.
Beat Ernst and colleagues explain that antibiotics are the mainstay treatment for UTIs. Bacteria, however, are developing resistance to common antibiotics, with the emergence of "superbugs" that shrug off some of the most powerful new antibiotics. Thus, the scientists decided to try a new approach developing substances that target bacteria virulence factors, inhibiting them from sticking to the inside of the urinary bladder. Hence, microbes are not able to launch an infection and, furthermore, this new class of antimicrobials is expected to exhibit less selection pressure and, therefore, a reduced potential for the emergence of resistance.
The scientists describe the development of anti-adhesion molecules that specifically interfere with the attachment of bacteria to human bladder cells. The most potent of the substances, an indolinylphenyl mannoside, prevented a UTI from developing in mice (stand-ins for humans in this kind of experiment) for more than eight hours. In the in vivo treatment study, a very low dose of 25 g per mouse reduced the amount of bacteria in the bladder of the animals by almost 10,000 times, which is comparable to the standard antibiotic treatment with ciprofloxacin.
###
The authors acknowledge funding from the Swiss National Science Foundation.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
superbowl halftime ufc 143 results kickoff time super bowl 2012 superbowl national anthem patriots vs giants super bowl superbowl halftime show papa johns
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.